3CPM
Private Company
Funding information not available
Overview
3CPM Corporation is a pioneer in electrogastrography (EGG), offering the only approved, non-invasive diagnostic system for characterizing gastric motility disorders. Its core platform integrates miniaturized hardware with patented, AI-based software to provide objective diagnoses and subtyping of conditions such as gastroparesis and functional dyspepsia, aiming to optimize therapy. Founded on decades of research, the company commercializes its EGG system and companion data management software for clinical and research settings. 3CPM operates as a private, commercial-stage diagnostics company targeting a significant unmet need in gastroenterology.
Technology Platform
Integrated hardware-software platform for non-invasive electrogastrography (EGG). Features miniaturized recording hardware and proprietary, AI-driven software (EGGSAS) that automates the acquisition, analysis, and diagnostic interpretation of gastric myoelectrical activity to subtype motility disorders.
Opportunities
Risk Factors
Competitive Landscape
3CPM holds a unique position as the only FDA-approved electrogastrography device. Direct competitors are limited, but it competes with established diagnostic methods like gastric emptying scintigraphy (for gastroparesis) and symptom-based diagnosis. Indirect competition may arise from new digital health tools, smart pills (e.g., motility-sensing capsules), and other bio-sensing technologies targeting GI function.